{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:10:49Z","timestamp":1794665449993,"version":"4.9.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R33 AI141184"],"award-info":[{"award-number":["R33 AI141184"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R33 AI141184"],"award-info":[{"award-number":["R33 AI141184"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R33 AI141184"],"award-info":[{"award-number":["R33 AI141184"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-52658-y","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T08:02:37Z","timestamp":1727424157000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Identification of potent and orally efficacious phosphodiesterase inhibitors in Cryptosporidium parvum-infected immunocompromised male mice"],"prefix":"10.1038","volume":"15","author":[{"given":"Jubilee","family":"Ajiboye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 E.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makafui","family":"Gasonoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan B.","family":"Mattice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Korwin-Mihavics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra C.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Stebbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Griggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5654-8919","authenticated-orcid":false,"given":"Thomas","family":"Spangenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-619X","authenticated-orcid":false,"given":"Marvin J.","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5393-139X","authenticated-orcid":false,"given":"Christopher D.","family":"Huston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"52658_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1473-3099(14)70772-8","volume":"15","author":"W Checkley","year":"2015","unstructured":"Checkley, W. et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect. Dis. 15, 85\u201394 (2015).","journal-title":"Lancet Infect. Dis."},{"key":"52658_CR2","first-page":"1","volume":"60","author":"MC Hlavsa","year":"2011","unstructured":"Hlavsa, M. C. et al. Surveillance for waterborne disease outbreaks and other health events associated with recreational water\u2013United States, 2007\u20132008. MMWR Surveill. Summ. 60, 1\u201332 (2011).","journal-title":"MMWR Surveill. Summ."},{"key":"52658_CR3","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/S0140-6736(16)31529-X","volume":"388","author":"J Liu","year":"2016","unstructured":"Liu, J. et al. Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study. Lancet 388, 1291\u20131301 (2016).","journal-title":"Lancet"},{"key":"52658_CR4","doi-asserted-by":"publisher","first-page":"e758","DOI":"10.1016\/S2214-109X(18)30283-3","volume":"6","author":"IA Khalil","year":"2018","unstructured":"Khalil, I. A. et al. Morbidity, mortality, and long-term consequences associated with diarrhoea from Cryptosporidium infection in children younger than 5 years: a meta-analyses study. Lancet Glob. Health 6, e758\u2013e768 (2018).","journal-title":"Lancet Glob. Health"},{"key":"52658_CR5","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/S0140-6736(02)11401-2","volume":"360","author":"B Amadi","year":"2002","unstructured":"Amadi, B. et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 360, 1375\u20131380 (2002).","journal-title":"Lancet"},{"key":"52658_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-9-195","volume":"9","author":"B Amadi","year":"2009","unstructured":"Amadi, B. et al. High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. BMC Infect. Dis. 9, 195 (2009).","journal-title":"BMC Infect. Dis."},{"key":"52658_CR7","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1128\/AAC.02641-13","volume":"58","author":"K Bessoff","year":"2014","unstructured":"Bessoff, K. et al. Identification of Cryptosporidium parvum active chemical series by Repurposing the open access malaria box. Antimicrob. Agents Chemother. 58, 2731\u20132739 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"52658_CR8","doi-asserted-by":"publisher","unstructured":"Buckner, F. S. et al. Optimization of methionyl tRNA-synthetase inhibitors for treatment of cryptosporidium infection. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.02061-18 (2019).","DOI":"10.1128\/AAC.02061-18"},{"key":"52658_CR9","doi-asserted-by":"publisher","first-page":"e0005373","DOI":"10.1371\/journal.pntd.0005373","volume":"11","author":"MS Love","year":"2017","unstructured":"Love, M. S. et al. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis. PLoS Negl. Trop. Dis. 11, e0005373 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"52658_CR10","doi-asserted-by":"publisher","first-page":"7015","DOI":"10.1073\/pnas.1814685116","volume":"116","author":"B Baragana","year":"2019","unstructured":"Baragana, B. et al. Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis. Proc. Natl Acad. Sci. USA 116, 7015\u20137020 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"52658_CR11","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1093\/infdis\/jit327","volume":"208","author":"A Castellanos-Gonzalez","year":"2013","unstructured":"Castellanos-Gonzalez, A. et al. A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis. J. Infect. Dis. 208, 1342\u20131348 (2013).","journal-title":"J. Infect. Dis."},{"key":"52658_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1021\/ml100096t","volume":"1","author":"RC Murphy","year":"2010","unstructured":"Murphy, R. C. et al. Discovery of potent and selective inhibitors of calcium-dependent protein kinase 1 (CDPK1) from C. parvum and T. gondii. ACS Med. Chem. Lett. 1, 331\u2013335 (2010).","journal-title":"ACS Med. Chem. Lett."},{"key":"52658_CR13","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/infdis\/jiw488","volume":"214","author":"DA Schaefer","year":"2016","unstructured":"Schaefer, D. A. et al. Novel bumped kinase inhibitors are safe and effective therapeutics in the calf clinical model for cryptosporidiosis. J. Infect. Dis. 214, 1856\u20131864 (2016).","journal-title":"J. Infect. Dis."},{"key":"52658_CR14","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/infdis\/jit645","volume":"209","author":"F Guo","year":"2014","unstructured":"Guo, F. et al. Amelioration of Cryptosporidium parvum infection in vitro and in vivo by targeting parasite fatty acyl-coenzyme A synthetases. J. Infect. Dis. 209, 1279\u20131287 (2014).","journal-title":"J. Infect. Dis."},{"key":"52658_CR15","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1093\/infdis\/jix689","volume":"217","author":"F Guo","year":"2018","unstructured":"Guo, F., Zhang, H., McNair, N. N., Mead, J. R. & Zhu, G. The existing drug vorinostat as a new lead against cryptosporidiosis by targeting the parasite histone deacetylases. J. Infect. Dis. 217, 1110\u20131117 (2018).","journal-title":"J. Infect. Dis."},{"key":"52658_CR16","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.str.2017.07.015","volume":"25","author":"V Jain","year":"2017","unstructured":"Jain, V. et al. Targeting prolyl-tRNA synthetase to accelerate drug discovery against malaria, leishmaniasis, toxoplasmosis, cryptosporidiosis, and coccidiosis. Structure 25, 1495\u20131505.e1496 (2017).","journal-title":"Structure"},{"key":"52658_CR17","doi-asserted-by":"publisher","unstructured":"Huang, W. et al. 5-Aminopyrazole-4-carboxamide-based compounds prevent the growth of cryptosporidium parvum. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00020-17 (2017).","DOI":"10.1128\/AAC.00020-17"},{"key":"52658_CR18","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nature22337","volume":"546","author":"UH Manjunatha","year":"2017","unstructured":"Manjunatha, U. H. et al. A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis. Nature 546, 376\u2013380 (2017).","journal-title":"Nature"},{"key":"52658_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10687-y","volume":"10","author":"CS Lunde","year":"2019","unstructured":"Lunde, C. S. et al. Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis. Nat. Commun. 10, 2816 (2019).","journal-title":"Nat. Commun."},{"key":"52658_CR20","doi-asserted-by":"publisher","first-page":"e01505","DOI":"10.1128\/AAC.01505-17","volume":"62","author":"RS Jumani","year":"2018","unstructured":"Jumani, R. S. et al. A novel piperazine-based drug lead for cryptosporidiosis from the medicines for malaria venture open-access malaria box. Antimicrob. Agents Chemother. 62, e01505\u2013e01517 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"52658_CR21","doi-asserted-by":"publisher","unstructured":"Vinayak, S. et al. Bicyclic azetidines kill the diarrheal pathogen Cryptosporidium in mice by inhibiting parasite phenylalanyl-tRNA synthetase. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aba8412 (2020).","DOI":"10.1126\/scitranslmed.aba8412"},{"key":"52658_CR22","doi-asserted-by":"publisher","first-page":"11729","DOI":"10.1021\/acs.jmedchem.1c01136","volume":"64","author":"E Oboh","year":"2021","unstructured":"Oboh, E. et al. Optimization of the urea linker of triazolopyridazine MMV665917 results in a new anticryptosporidial lead with improved potency and predicted hERG safety margin. J. Med. Chem. 64, 11729\u201311745 (2021).","journal-title":"J. Med. Chem."},{"key":"52658_CR23","doi-asserted-by":"publisher","unstructured":"Hasan, M. M. et al. Spontaneous selection of cryptosporidium drug resistance in a calf model of infection. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00023-21 (2021).","DOI":"10.1128\/AAC.00023-21"},{"key":"52658_CR24","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S0166-2236(02)02236-1","volume":"25","author":"J Heemskerk","year":"2002","unstructured":"Heemskerk, J., Tobin, A. J. & Bain, L. J. Teaching old drugs new tricks. Meeting of the Neurodegeneration Drug Screening Consortium, 7-8 April 2002, Washington, DC, USA. Trends Neurosci. 25, 494\u2013496 (2002).","journal-title":"Trends Neurosci."},{"key":"52658_CR25","doi-asserted-by":"publisher","first-page":"e0267038","DOI":"10.1371\/journal.pone.0267038","volume":"17","author":"G De Pascale","year":"2022","unstructured":"De Pascale, G. et al. Remdesivir plus Dexamethasone in COVID-19: a cohort study of severe patients requiring high flow oxygen therapy or non-invasive ventilation. PLoS ONE 17, e0267038 (2022).","journal-title":"PLoS ONE"},{"key":"52658_CR26","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1021\/acs.jcim.0c00861","volume":"60","author":"A Edwards","year":"2020","unstructured":"Edwards, A. What are the odds of finding a COVID-19 drug from a lab repurposing screen? J. Chem. Inf. Model. 60, 5727\u20135729 (2020).","journal-title":"J. Chem. Inf. Model."},{"key":"52658_CR27","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1128\/AAC.02460-12","volume":"57","author":"K Bessoff","year":"2013","unstructured":"Bessoff, K., Sateriale, A., Lee, K. K. & Huston, C. D. Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth. Antimicrob. Agents Chemother. 57, 1804\u20131814 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"52658_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/infdis\/jix247","volume":"216","author":"SLM Arnold","year":"2017","unstructured":"Arnold, S. L. M. et al. Necessity of bumped kinase inhibitor gastrointestinal exposure in treating Cryptosporidium infection. J. Infect. Dis. 216, 55\u201363 (2017).","journal-title":"J. Infect. Dis."},{"key":"52658_CR29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/cid\/ciaa421","volume":"73","author":"P Iroh Tam","year":"2021","unstructured":"Iroh Tam, P. et al. Clofazimine for treatment of cryptosporidiosis in human immunodeficiency virus infected adults: an experimental medicine, randomized, double-blind, placebo-controlled phase 2a trial. Clin. Infect. Dis. 73, 183\u2013191 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"52658_CR30","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S1359-6446(05)03686-X","volume":"11","author":"CG Wermuth","year":"2006","unstructured":"Wermuth, C. G. Selective optimization of side activities: the SOSA approach. Drug Discov. Today 11, 160\u2013164 (2006).","journal-title":"Drug Discov. Today"},{"key":"52658_CR31","unstructured":"Merck-KGaA. Biopharma Mini Library, <https:\/\/www.emdgroup.com\/en\/research\/open-innovation\/biopharma-open-innovation-portal\/biopharma-mini-library.html> (2023)."},{"key":"52658_CR32","unstructured":"Merck-KGaA. Open Global Health Library, <https:\/\/www.emdgroup.com\/en\/research\/open-innovation\/biopharma-open-innovation-portal\/open-global-health-library.html> (2023)."},{"key":"52658_CR33","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1021\/jm901137j","volume":"53","author":"JB Baell","year":"2010","unstructured":"Baell, J. B. & Holloway, G. A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 53, 2719\u20132740 (2010).","journal-title":"J. Med. Chem."},{"key":"52658_CR34","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/nm1284","volume":"11","author":"M Camps","year":"2005","unstructured":"Camps, M. et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11, 936\u2013943 (2005).","journal-title":"Nat. Med."},{"key":"52658_CR35","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1021\/jm0601598","volume":"49","author":"V Pomel","year":"2006","unstructured":"Pomel, V. et al. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J. Med. Chem. 49, 3857\u20133871 (2006).","journal-title":"J. Med. Chem."},{"key":"52658_CR36","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1021\/jm401411z","volume":"57","author":"G Maggiora","year":"2014","unstructured":"Maggiora, G., Vogt, M., Stumpfe, D. & Bajorath, J. Molecular similarity in medicinal chemistry. J. Med. Chem. 57, 3186\u20133204 (2014).","journal-title":"J. Med. Chem."},{"key":"52658_CR37","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1021\/jm00307a017","volume":"11","author":"HA Burch","year":"1968","unstructured":"Burch, H. A. Nitrofuryl heterocycles. VII. 4-Amino-6-(5-nitro-2-furyl)-1H-pyrazolo[3,4-d]pyrimidines. J. Med. Chem. 11, 79\u201383 (1968).","journal-title":"J. Med. Chem."},{"key":"52658_CR38","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/jac\/dkm476","volume":"61","author":"JW Mouton","year":"2008","unstructured":"Mouton, J. W. et al. Tissue concentrations: do we ever learn? J. Antimicrob. Chemother. 61, 235\u2013237 (2008).","journal-title":"J. Antimicrob. Chemother."},{"key":"52658_CR39","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.bmc.2011.10.022","volume":"20","author":"DJ Rawson","year":"2012","unstructured":"Rawson, D. J. et al. The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics. Bioorg. Med. Chem. 20, 498\u2013509 (2012).","journal-title":"Bioorg. Med. Chem."},{"key":"52658_CR40","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ejmech.2012.12.009","volume":"60","author":"J Fiorito","year":"2013","unstructured":"Fiorito, J. et al. Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer\u2019s disease. Eur. J. Med. Chem. 60, 285\u2013294 (2013).","journal-title":"Eur. J. Med. Chem."},{"key":"52658_CR41","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.03056-23","volume":"15","author":"WJ Moss","year":"2024","unstructured":"Moss, W. J., Brusini, L., Kuehnel, R., Brochet, M. & Brown, K. M. Apicomplexan phosphodiesterases in cyclic nucleotide turnover: conservation, function, and therapeutic potential. mBio 15, e0305623 (2024).","journal-title":"mBio"},{"key":"52658_CR42","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41586-024-07466-1","volume":"630","author":"KA Walzer","year":"2024","unstructured":"Walzer, K. A. et al. Transcriptional control of the Cryptosporidium life cycle. Nature 630, 174\u2013180 (2024).","journal-title":"Nature"},{"key":"52658_CR43","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1038\/s41564-019-0539-x","volume":"4","author":"J Tandel","year":"2019","unstructured":"Tandel, J. et al. Life cycle progression and sexual development of the apicomplexan parasite Cryptosporidium parvum. Nat. Microbiol. 4, 2226\u20132236 (2019).","journal-title":"Nat. Microbiol."},{"key":"52658_CR44","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"52658_CR45","doi-asserted-by":"publisher","first-page":"D439","DOI":"10.1093\/nar\/gkab1061","volume":"50","author":"M Varadi","year":"2022","unstructured":"Varadi, M. et al. AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 50, D439\u2013D444 (2022).","journal-title":"Nucleic Acids Res."},{"key":"52658_CR46","unstructured":"Brown, D. G. et al. The structure of Schistosoma mansoni Phospohodiesterase 4A in complex with cAMP. (RCSB Protein Data Bank, 2018)."},{"key":"52658_CR47","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","volume":"47","author":"RA Friesner","year":"2004","unstructured":"Friesner, R. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47, 1739\u20131749 (2004).","journal-title":"J. Med. Chem."},{"key":"52658_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09880-w","volume":"10","author":"RS Jumani","year":"2019","unstructured":"Jumani, R. S. et al. A suite of phenotypic assays to ensure pipeline diversity when prioritizing drug-like Cryptosporidium growth inhibitors. Nat. Commun. 10, 1862 (2019).","journal-title":"Nat. Commun."},{"key":"52658_CR49","unstructured":"Eurofins. In Vitro Safety Pharmacology Profiling Panels. <https:\/\/www.eurofinsdiscovery.com\/solution\/safety-panels> (2023)."},{"key":"52658_CR50","doi-asserted-by":"publisher","first-page":"W257","DOI":"10.1093\/nar\/gky318","volume":"46","author":"P Banerjee","year":"2018","unstructured":"Banerjee, P., Eckert, A. O., Schrey, A. K. & Preissner, R. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 46, W257\u2013W263 (2018).","journal-title":"Nucleic Acids Res."},{"key":"52658_CR51","doi-asserted-by":"publisher","first-page":"e3001604","DOI":"10.1371\/journal.pbio.3001604","volume":"20","author":"ED English","year":"2022","unstructured":"English, E. D., Guerin, A., Tandel, J. & Striepen, B. Live imaging of the Cryptosporidium parvum life cycle reveals direct development of male and female gametes from type I meronts. PLoS Biol. 20, e3001604 (2022).","journal-title":"PLoS Biol."},{"key":"52658_CR52","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1645\/0022-3395(2002)088[1014:STCPII]2.0.CO;2","volume":"88","author":"LD Campbell","year":"2002","unstructured":"Campbell, L. D., Stewart, J. N. & Mead, J. R. Susceptibility to Cryptosporidium parvum infections in cytokine- and chemokine-receptor knockout mice. J. Parasitol. 88, 1014\u20131016 (2002).","journal-title":"J. Parasitol."},{"key":"52658_CR53","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1006\/expr.2001.4627","volume":"98","author":"LM Smith","year":"2001","unstructured":"Smith, L. M., Bonafonte, M. T., Campbell, L. D. & Mead, J. R. Exogenous interleukin-12 (IL-12) exacerbates Cryptosporidium parvum infection in gamma interferon knockout mice. Exp. Parasitol. 98, 123\u2013133 (2001).","journal-title":"Exp. Parasitol."},{"key":"52658_CR54","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1128\/AAC.02075-13","volume":"58","author":"SK Gorla","year":"2014","unstructured":"Gorla, S. K. et al. Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis. Antimicrob. Agents Chemother. 58, 1603\u20131614 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"52658_CR55","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.bmc.2016.02.032","volume":"24","author":"J Veerman","year":"2016","unstructured":"Veerman, J. et al. Synthesis and evaluation of analogs of the phenylpyridazinone NPD-001 as potent trypanosomal TbrPDEB1 phosphodiesterase inhibitors and in vitro trypanocidals. Bioorg. Med. Chem. 24, 1573\u20131581 (2016).","journal-title":"Bioorg. Med. Chem."},{"key":"52658_CR56","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1021\/acs.jmedchem.7b01670","volume":"61","author":"AR Blaazer","year":"2018","unstructured":"Blaazer, A. R. et al. Targeting a subpocket in Trypanosoma brucei Phosphodiesterase B1 (TbrPDEB1) enables the structure-based discovery of selective inhibitors with trypanocidal activity. J. Med. Chem. 61, 3870\u20133888 (2018).","journal-title":"J. Med. Chem."},{"key":"52658_CR57","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1016\/j.bmc.2019.06.027","volume":"27","author":"E de Heuvel","year":"2019","unstructured":"de Heuvel, E. et al. Alkynamide phthalazinones as a new class of TbrPDEB1 inhibitors. Bioorg. Med. Chem. 27, 3998\u20134012 (2019).","journal-title":"Bioorg. Med. Chem."},{"key":"52658_CR58","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1016\/j.tetlet.2015.04.061","volume":"56","author":"E Amata","year":"2015","unstructured":"Amata, E., Bland, N. D., Campbell, R. K. & Pollastri, M. P. Evaluation of pyrrolidine and pyrazolone derivatives as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1). Tetrahedron Lett. 56, 2832\u20132835 (2015).","journal-title":"Tetrahedron Lett."},{"key":"52658_CR59","doi-asserted-by":"publisher","first-page":"10252","DOI":"10.1021\/acs.jmedchem.3c00161","volume":"66","author":"Y Zheng","year":"2023","unstructured":"Zheng, Y. et al. Discovery of 5-phenylpyrazolopyrimidinone analogs as potent antitrypanosomal agents with in vivo efficacy. J. Med. Chem. 66, 10252\u201310264 (2023).","journal-title":"J. Med. Chem."},{"key":"52658_CR60","doi-asserted-by":"publisher","first-page":"e0005680","DOI":"10.1371\/journal.pntd.0005680","volume":"11","author":"T Long","year":"2017","unstructured":"Long, T. et al. Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target. PLoS Negl. Trop. Dis. 11, e0005680 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"52658_CR61","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.4155\/fmc-2018-0592","volume":"11","author":"V Sebastian-Perez","year":"2019","unstructured":"Sebastian-Perez, V. et al. Discovery of novel Schistosoma mansoni PDE4A inhibitors as potential agents against schistosomiasis. Future Med. Chem. 11, 1703\u20131720 (2019).","journal-title":"Future Med. Chem."},{"key":"52658_CR62","doi-asserted-by":"publisher","unstructured":"Zheng, Y. et al. To target or not to target schistosoma mansoni cyclic nucleotide phosphodiesterase 4A? Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms24076817 (2023).","DOI":"10.3390\/ijms24076817"},{"key":"52658_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.exppara.2019.107793","volume":"208","author":"SS Botros","year":"2020","unstructured":"Botros, S. S. et al. The phosphodiesterase-4 inhibitor roflumilast impacts Schistosoma mansoni ovipositing in vitro but displays only modest antischistosomal activity in vivo. Exp. Parasitol. 208, 107793 (2020).","journal-title":"Exp. Parasitol."},{"key":"52658_CR64","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1021\/cb501004q","volume":"10","author":"BL Howard","year":"2015","unstructured":"Howard, B. L. et al. Identification of potent phosphodiesterase inhibitors that demonstrate cyclic nucleotide-dependent functions in apicomplexan parasites. ACS Chem. Biol. 10, 1145\u20131154 (2015).","journal-title":"ACS Chem. Biol."},{"key":"52658_CR65","doi-asserted-by":"publisher","unstructured":"Zheng, Y. et al. Structural optimization of BIPPO analogs as potent antimalarials. Molecules https:\/\/doi.org\/10.3390\/molecules28134939 (2023).","DOI":"10.3390\/molecules28134939"},{"key":"52658_CR66","doi-asserted-by":"crossref","first-page":"56S","DOI":"10.1111\/j.1550-7408.1999.tb04584.x","volume":"46","author":"J Gut","year":"1999","unstructured":"Gut, J. & Nelson, R. G. Cryptosporidium parvum: synchronized excystation in vitro and evaluation of sporozoite infectivity with a new lectin-based assay. J. Eukaryot. Microbiol. 46, 56S\u201357S (1999).","journal-title":"J. Eukaryot. Microbiol."},{"key":"52658_CR67","doi-asserted-by":"publisher","first-page":"938","DOI":"10.4269\/ajtmh.2007.76.938","volume":"76","author":"JB Parr","year":"2007","unstructured":"Parr, J. B. et al. Detection and quantification of Cryptosporidium in HCT-8 cells and human fecal specimens using real-time polymerase chain reaction. Am. J. Trop. Med. Hyg. 76, 938\u2013942 (2007).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"52658_CR68","doi-asserted-by":"publisher","first-page":"D898","DOI":"10.1093\/nar\/gkab929","volume":"50","author":"B Amos","year":"2022","unstructured":"Amos, B. et al. VEuPathDB: the eukaryotic pathogen, vector and host bioinformatics resource center. Nucleic Acids Res. 50, D898\u2013D911 (2022).","journal-title":"Nucleic Acids Res."},{"key":"52658_CR69","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0022-2836(05)80360-2","volume":"215","author":"SF Altschul","year":"1990","unstructured":"Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. J. Mol. Biol. 215, 403\u2013410 (1990).","journal-title":"J. Mol. Biol."},{"key":"52658_CR70","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature14651","volume":"523","author":"S Vinayak","year":"2015","unstructured":"Vinayak, S. et al. Genetic modification of the diarrhoeal pathogen Cryptosporidium parvum. Nature 523, 477\u2013480 (2015).","journal-title":"Nature"},{"key":"52658_CR71","doi-asserted-by":"publisher","first-page":"20B 22 21","DOI":"10.1002\/cpmc.33","volume":"46","author":"MC Pawlowic","year":"2017","unstructured":"Pawlowic, M. C., Vinayak, S., Sateriale, A., Brooks, C. F. & Striepen, B. Generating and maintaining transgenic Cryptosporidium parvum parasites. Curr. Protoc. Microbiol. 46, 20B 22 21\u201320B 22 32 (2017).","journal-title":"Curr. Protoc. Microbiol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52658-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52658-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52658-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T08:06:05Z","timestamp":1727424365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52658-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["52658"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-52658-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"26 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.D.H., M.J.M., and M.G. are inventors on a pending patent application jointly filed by the University of Vermont and St. Louis University that covers use of pyrazolopyrimidines as anti-infective agents (PCT Application No. 63\/504,716 filed May 26, 2023). All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8272"}}